Harrow jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States."We are thrilled to be working alongside iOR Partners as they mobilize an increasing number of cataract surgeons to perform surgery in an office-based environment, offering more personalized care in a patient-friendly setting," said Mark L. Baum, Chairman and CEO of Harrow. "iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality. Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HROW:
